Kayvon Ghavoumi

I'll research this attorney's professional background before drafting.

Let me verify the tracked case and PTAB experience.

Note on name: The tracked profile lists "Kayvon Ghavoumi." The attorney's name is spelled Kayvon Ghayoumi on his firm bio and in Federal Circuit opinions (one docket renders it "Kayvon M. Ghavoumi"; New York attorney registration lists "Kayvon Miles Ghayoumi"). I treated these as the same person; the summary below uses the firm's spelling.

---

Practice focus. Ghayoumi is an appellate and complex-litigation associate at MoloLamken whose practice centers on patent appeals in the U.S. Court of Appeals for the Federal Circuit, with supporting district court work. His docket is technology-diverse rather than concentrated in one art: biologics and pharmaceutical formulation disputes (BPCIA and Hatch-Waxman), memory-module and semiconductor patents, telecommunications/5G standard-essential patents and FRAND/antisuit disputes, agricultural crop-protection chemicals, and printing/imaging hardware on appeal from PTAB proceedings. That breadth is consistent with an appellate boutique practice, where he is typically briefed in at the Federal Circuit stage rather than acting as a first-chair trial lawyer.

Side preference. The tracked data (0 plaintiff / 1 defendant) understates the range of his work because it reflects a single logged appearance. In Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (Fed. Cir. 24-2351) he was part of the MoloLamken team representing Amgen as defendant-appellee, defending the denial of a preliminary injunction on the aflibercept '865 patent. Firm-listed matters show he has also appeared for patent owners and plaintiffs on appeal, including Netlist (memory modules) and Ericsson (5G SEPs). On the available record he is better described as defense-leaning in the tracked matters but a both-sides appellate specialist, not an NPE/PAE-focused prosecutor.

Firm context and notable matters. He is at MoloLamken (New York and Washington, D.C.), an appellate and trial boutique, and previously practiced as an associate at Finnegan, Henderson, Farabow, Garrett & Dunner. Verifiable outcomes include Ericsson v. Lenovo (Fed. Cir. 24-1515, argued by Jeffrey Lamken with Ghayoumi on the brief), where the Federal Circuit on October 24, 2024 vacated the district court's denial of Lenovo's antisuit injunction and remanded; Regeneron v. Amgen, where the Federal Circuit affirmed the denial of a preliminary injunction on March 14, 2025, holding Amgen's aflibercept biosimilar did not contain the separately claimed "buffer" element under Becton; and Slingshot Printing LLC v. Canon U.S.A., in which he argued for the appellant and the Federal Circuit affirmed the Board without opinion (Rule 36) in May 2026. Firm materials also list work defending large jury verdicts in memory-module and telecommunications appeals and a $30 million pharmaceutical verdict, but those matters are described generically and I could not verify the specific case names or outcomes.

PTAB / IPR experience. He appears in appeals from PTAB proceedings rather than as a first-instance IPR petitioner. Federal Circuit argument in Slingshot v. Canon arose from IPR2022-01416 and IPR2023-00309, and he is listed on a series of Netlist appeals challenging Board unpatentability rulings (Netlist v. Samsung, Netlist v. Micron). Treat this as PTAB-adjacent appellate experience; there is no public indication he files or litigates IPRs at the Board.

Bar and education. J.D., George Washington University Law School (highest honors, Order of the Coif, Notes Editor, GW Law Review); B.A., University of Kentucky; admitted in New York and the District of Columbia, and before the Federal, Fifth, and Veterans Claims Circuits. He clerked for Judge Richard G. Taranto of the Federal Circuit.